Marks’s Nanopatch™ idea was to offer a needle-free method of drug delivery that could be widely used and increase vaccine efficacy.
In 2011 UniQuest, the University of Queensland’s commercialisation company, helped Mark found Vaxxas to advance the possibility of Nanopatch™ becoming a clinically-proven product.
Today, Vaxxas and Mark are getting closer to making that idea a reality by raising £12.7 million of funding for a series of clinical programs and the development of a pipeline of new vaccine products for major diseases.
WPV3 has not been detected for more than two years. The last reported case of Wild Poliovirus Type 2 (WPV2) was in India in 1999.
The completion of polio eradication was declared a programmatic emergency for public health in 2012, and the international spread of Wild Poliovirus Type 1 (WPV1) was declared a public health emergency of international concern in May 2014.
The efforts needed to interrupt all indigenous WPV1 transmission are now being focused on the remaining endemic countries: Nigeria, Afghanistan, and Pakistan.
Mankind’s ability to transform public health in this way is impressive. Let’s hope we can achieve the same results with Ebola.